5,5-fused arylene or heteroarylene hepatitis C virus inhibitors

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 9187496
APP PUB NO 20130071352A1
SERIAL NO

13675787

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

Provided herein are 5,5-fused heteroarylene hepatitis C virus inhibitor compounds, for example, of Formula I, IA, or IB, pharmaceutical compositions comprising the compounds, and processes of preparation thereof. Also provided are methods of their use for the treatment of an HCV infection in a host in need thereof.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
IDENIX PHARMACEUTICALS LLC320 BENT STREET FLOOR 4 CAMBRIDGE MA 02141

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Alexandre, Francois-Rene Montpellier, FR 29 506
Brandt, Guillaume Montpellier, FR 7 171
Convard, Thierry Sathonay-Camp, FR 14 174
Da, Costa Daniel Saint Jean de Vedas, FR 7 156
Derock, Michel Grabels, FR 8 216
Dousson, Cyril B Canet, FR 34 659
Dukhan, David Saint Gely du Fesc, FR 40 749
Paparin, Jean-Laurent Vendemian, FR 25 224
Parsy, Christophe Claude Jacou, FR 31 549
Pierra, Claire Montarnaud, FR 24 834
Rahali, Houcine Saint Laurent des Arbres, FR 13 273
Surleraux, Dominique Wauthier-Braine, BE 35 756

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
11.5 Year Payment $7400.00 $3700.00 $1850.00 May 17, 2027
Fee Large entity fee small entity fee micro entity fee
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00